The Potential of Imlifidase 2021 International Clinical Webinar

Imlifidase specifically targets IgG and inhibits pathogenic IgG-mediated immune responses in transplant patients and patients with autoimmune disease or cancer. Imlifidase infusion has a better safety profile than plasmapheresis, and three patients in a clinical phase II trial received two doses within a 24-hour period without experiencing allergic reactions. Imlifidase is currently approved for sensitized transplant candidates in the European Union who are receiving organs from deceased donors, but it is under consideration as a treatment for patients receiving organs from living donors.